Thermosensitive Intracavitary Hemostatic Agent

Period of Performance: 01/18/2006 - 01/18/2007


Phase 1 SBIR

Recipient Firm

Luna Innovations, Inc.
301 1st St Suite 200
Roanoke, VA 24011
Principal Investigator


Hemorrhage is the leading cause of death from battlefield trauma. Approximately 80% of hemorrhagic deaths on the battlefield are due to intracavitary hemorrhage that is not accessible to direct pressure. Noncompressible hemorrhage is also a primary cause of death in civilian trauma. Unfortunately, methods available to first responders to control hemorrhage are only useful for extremity or superficial truncal injuries and the only viable treatment for intracavitary hemorrhage is surgical intervention. Luna Innovations proposes to develop an intracavitary hemostatic agent from a thermosensitive sol-gel system that is liquid at room temperature, but gel at 37° C. This novel agent will allow easy delivery of a unique, low-viscosity, neutral pH solution that rapidly increases in viscosity and forms a biocompatible, bioadhesive, biodegradable and hemostatic physical gel within the body cavity. The gelling hemostatic agent will be administered by a delivery system that will provide sufficient tamponade to control capillary/venous bleeding and surface oozing, allow interaction of the agent with injured tissues in the vicinity of pooled and/or flowing blood, and provide an ability to gauge proper positioning and real time assessment of success. The stored and transported liquid hemostatic agent and delivery system will be stable, small, lightweight, low-cost and easy to use.